Oragenics, Inc.
OGEN · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.16 | 0.30 |
| FCF Yield | -4,701.78% | -18,410.34% | -2.75% | -2.64% |
| EV / EBITDA | -0.61 | 0.42 | -21.82 | -29.37 |
| Quality | ||||
| ROIC | -80.11% | -75.26% | -2,876.30% | -67.75% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.58 | 0.95 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 37.77% | -4.64% | -2.44% | -27.56% |
| Safety | ||||
| Net Debt / EBITDA | -0.60 | 0.43 | 0.16 | 1.07 |
| Interest Coverage | -3.00 | -10.17 | -305.86 | -244.41 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -203.56 | -65.62 | -154.94 |